Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension☆
To access this article, please choose from the options below
☆ This study was sponsored by an unrestricted educational grant from Allergan, Inc., Irvine, CA. The authors have no proprietary interest in bimatoprost or Allergan, Inc.
PII: S0039-6257(03)00190-5
doi:10.1016/j.survophthal.2003.12.015
© 2004 Elsevier Inc. All rights reserved.
